Browse > Article

The Effect of Tetramethoxyflavone on the Pharmacokinetics of Paclitaxel in Rats  

나종학 (조선대학교 약학대학)
백채선 (조선대학교 약학대학)
최준식 (조선대학교 약학대학)
Publication Information
YAKHAK HOEJI / v.48, no.4, 2004 , pp. 226-230 More about this Journal
Abstract
The pharmacokinetics of orally administered paclitlxel (50 mg/kg) was studied in six rabbits after 1hr pretreatment (2.0 mg/kg and 10 mg/kg) of tetramethoxyflavone or coadministration of (2.0 mg/kg, 10 mg/kg and 20 mg/kg) tetramethoxyflavone. The area under the plasma concentration-tine curve (AUC) and plasma concentration of paclitaxe1 coadministered with tetramethoxyflavone (10 mglkg) were increased significantly (p<0.05) compared with control. However, coadministration of tetramethoxyflavone (2 and 20 mg/kg) showed no significant effect on the pharmacokinetic parameters of paclitaxel. Pretreatment with tetramethoxyflavone significantly (p<0.05) increased the plasma concentration of paclitaxel. The area under the plasma concentration-time curve (AUC) and the peak concentration (C$_{max}$) of paclitaxel pretreated with tetramethoxyflavone were increased significantly (p<0.01, p<0.05) compared with control. The terminal half. life of paclitaxel pretreated with tetramethoxyflavone (2 mg/kg and 10 mg/kg) was significantly (p<0.05) prolonged compared with control. Pretreatment with tetramethoxyflavone (2.0 mg/kg, 10 mg/kg) significantly (p<0.01, p<0.05) increased the absolute bioavailability of paclitaxel compared with the control (154∼179%). On the basis of the results, it might be considered that tetramethoxyflavone may inhibit cytochrome P450 or P-glycoprotein efflux pump which are engaged in paclitaxel metabolism, result in increased AUC and t$_{1}$2/ of paclitaxel. However, further study should be conducted to clarify the roles of cytochrome P450 and P-glycoprotein on paclitaxel bioavailability with/or without tetramethoxyflavone. P-glycoprotein on paclitaxel bioavailability with/or without tetramethoxyflavone.
Keywords
paclitaxel; pharmacokinetics; tetramethoxyflavone; coadministration; pretreatment;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Einzig, A. I., Hochster, H., Wiernik , P. H. et al. : A phase II study of taxol in patients with malignant melanoma. Invest. New. Drugs. 9, 59 (1991)
2 Grem, J. L., Tutsch, K. D., Simon, K. L. et al. : Phase I study of taxol administered as a short iv infusion daily for 5 days. Cancer Treat. Rep. 71, 1179 (1987)
3 Watkins, P. B. : The barrier function of CYP3A4 and Pglycoprotein in the small bowel. Adv. Drug Deliv. Rev. 27, 161 (1997)   DOI   PUBMED   ScienceOn
4 Sonnichsen, D. S., Liu, Q., Schuetz, E. G., Schuetz, J. D., Pappo, A. and Reiling, M. V. : Variability in human cytochrome P450 paclitaxel metabolism.J. Pharmacol. Exp. Ther. 275 , 566 (1995)
5 Ikegawa, T., Ohtani, H., Koyabu, N., Juichi, M., Iwase, Y., Ito, C., Furukawa, H., Naito, M., Tsuruo, T. and Sawada, Y. : Inhibition of P-glycoprotein by flavonoid derivatives in adriamycin-resistant human myelogenous leukemia (K562/ADM) cells. Cancer Lett. 177, 89 (2002)   DOI   ScienceOn
6 Yenjai, C., Prasanphen, K., Daodee, S., Wongpanich, V. and Kittakoop, P. : Bioactive flavonoids from Kaempferia parviflora. Fitoterapia . 75, 89 (2004)   DOI   ScienceOn
7 Mase, H., Hiraoka, M. and Suzuki, F : Determination of new anticancer drug, paclitaxel, in biological fluids by high performance liquid chromatography. Yakugaku. Zasshi. 114, 351 (1994)
8 Wiernik, P. H., Schwartz, E. I., Einzig, A. et al. : Phase I trial of taxol given as a 24-hour infusion every 21 days: Responses seen in metastatic melanoma. J. Clin. Omcol. 5, 1232 (1987)
9 Choi, C. H., Romiti, N., Cervelli, F. and Tongiani, R. : Effect of flavonols on P-glycoprotein activety in cultured rat hepatocytes. Life Sciences 57, 1741 (1995)   DOI   ScienceOn
10 Rocci, M. L. and Jusko, W. J. : LAGRAN program for area and monents in pharmacokinetic analysis. Computer Program in Biomedicine. 16, 203 (1983)   DOI   ScienceOn
11 Sarosy, G., Kohn, E.,Stone, D. A. et al. : Phase I study of taxol and granulocyte stimulation factor in patients with refractory ovarian cancer. J. Clin. Oncol. 10, 1165 (1992)
12 McGuire, W. P., Rowinsky, E. K., Rosenheim, N. B. et al. : Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasm. Ann. Intern. Med. 111, 273 (1989)
13 Choi, C. H., Sun, K. H., An, C. S., Yoo, J. C., Hahm, K. S., Lee, I.H., Sohng, J. K. and Kim, Y. C. : Reversal of P-glycoprotein mediated multidrug resistance by 5,6,7,3’,4’-pentamethoxy-flavone (Sinensetin). Biochem. Biophys. Res. Commun . 295, 832 (2002)   DOI   ScienceOn
14 Souza, M. F, Tome, A. R. and Rao, V. S. : Inhibition by the bioflavonoid ternatin of aflatoxin B1-induced lipid peroxidation in rat liver. J. Pharm. Pharmacol. 51, 125 (1999)   DOI   ScienceOn
15 Rowinsky, E. K., Gilbert , M. R., McGuire, W. P. et al. : Sequences of taxol and cisplatin: A phase I and pharmacologic study. J. Clin. Oncol. 9, 1692 (1991)
16 Wacher V. H., Silverman, J. A., Zhang, Y. and Benet, L. Z. : Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci. 87, 1322 (1998)   DOI
17 Koide, T., Kamei, H., Hashimoto, Y., Kojima, T., Terabe , K. and Umeda, T. : Influence of flavonoids on cell cycle phase as analyzed by flowcytometry. Cancer Biother Badiopharm. 12, 111 (1997)   DOI   ScienceOn
18 Kutz, B. S., Wellzel, U. and Daniel, H. : Comparative analysis of the effects of flavonoids on proliferation, cytotoxicity, and apoptosis in human colon cancer cell lines. Eur.J. Nutr. 38, 133 (1999)   DOI   ScienceOn
19 Conseil, G., Baubichon-cortary, H., Dayan, G., Jault, J. M., Barron, D. and dl Pietro , A. : Flavonoids : a class of modulators with bifunctional interactions at vicinal ATP-and steroid binding sites on mouse P-glycorortein. Proc. Natl. Acad. Sci. USA 95, 9831 (1998)
20 Choi, J. S., Choi, H K. and Shin, S. C.: Enhanced bioavailability of paclitaxel after oral coadministration with flavone in rats. Int. J. Pharm. 275, 165 (2004)   DOI   PUBMED   ScienceOn
21 Kumar, G. N., Walle, U. K. and Walle, T : Cytochrome P450 3A-mediated human liver microsomal taxol 6$\alpha$-hydroxylation. J. Pharmacol. Exp. Ther. 268(3), 1160 (1994)
22 Ito, K., Kusuhara, H. and Sugiyama, Y. : Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption-theoretical approach. Pharm. Res. 16, 225 (1999)   DOI   ScienceOn
23 Soambia, G., Ranelletti, F. O., Panici, P. B., Vincenzo, De R., Bonanno, G., Frrandina, G., Piantelli, M., Bussa, S., Rumi, C., Ciantriglia, M. et al. : Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breastcancer cell line : P-glycoprotein as a possible target. Cancer Chemother Pharmacol. 36, 448 (1995)
24 Walle, T. : Short communication; Taxol metabolism in rat hepatocytes. Biochem. Pharmacol. 46, 1661 (1993)   DOI   ScienceOn
25 Sonnichsen, D. S. and Reiling, M. V. : Clinical Pharmacokinetics of paclitaxel. Clin. Pharmacokinet. 27, 256 (1994)   DOI   ScienceOn
26 Choi, J. S., Jo, B. W. and Kim, Y. C. : Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur.J. Pharm. Biopharm. 57, 313 (2004)   DOI   ScienceOn
27 Donehower R. C., Rowinsky, E. K., Grochow, L. B. et al. : Phase I trial of taxol in patients with advanced malignancies. cancer Treat. Rep. 71, 1171 (1987)
28 Doostdar, H., Burke, M. D. and Mayer, R. T. : Bioflavoniods : selective substrates and inhibitors for cytochrome P450 CYPIA and CYPIB1. Toxicology 144, 31 (2000)   DOI   PUBMED   ScienceOn
29 Legha, S. S., Tenney, D. M. and Krakhoff, I. R. : Phase I study of taxol using a 5-day intermittent schedule. J. Clin. Oncol. 5, 1232 (1987)
30 Harris, J. W., Rahman, A., Kim, B. R., Guengerich, F. P. and Collins, J. M. : Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 54, 4026 (1994)
31 Zhang, H., Wong, C. W., Coville, P. G. and Wanwimo.ruk, S.: Effect of the grapefruit flavonoid naringen on pharmacokinetics of quinine in rats. Drug Metabol. Drug Interact . 17,351 (2000)
32 Nagao, T., Abe, F, Kinjo, J. and Okabe, H. : Antipreliferative constituents in plants 10. Flavones from the leaves of Lantana montevidensis Briq. and consideration of structure-activity relationship. Biol. Pharm. Bull. 25, 875 (2002)
33 Einzig, A. I., Wiernik, P. H., Saslooff, J. et al. : Phase II study and long-term follow up of patients treated with taxol for advanced ovarian adenocarcinoma. J. Clin. Oncol. 10, 1748 (1992)
34 Rahman, A., Korzekwa, K. R., Grogan, J., Gonzalez, F. J. and Harris, J. W. : Selective biotransformation of taxol to 6 $\alpha$-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 54, 5543 (1994).
35 Rao, V. S., Figueiredo, E. G., Melo, C. L., Viana, G. S., Menezes, D. B., Matos, M. S. and Silveira, E. R. : Protective effect of ternatin, a flavonoid isolated from Egletes viscosa less. , in experimental liver injury. Pharmacology 48, 392 (1994)
36 Marin, N., Catalin, J., Blachon, M. F. and Durand, A. : Assay of paclitaxel (Taxol) in plasma and urine by high performance liquid chromatogrphy. J. Chromato. B. 709 , 281-288 (1998)
37 Einzig, A. I., Gorowski, E., Sadloff, J. et al. : Phase II trial of taxol in patients with metastatic renal cell carcinoma. Cancer Invest. 9, 133 (1991)   DOI   ScienceOn